The PRECIOUS (scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy) project aims to establish a nanoparticle platform for combinational cancer immunotherapy. This project is coordinated by Prof. Dr. Carl Figdor from the Tumor Immunology Department of the Radboud University Medical Center, the Netherlands. PRECIOUS is a collaboration between 5 leading institutes (RadboudUMC, University of Konstanz, Institute of Macromolecular Chemistry ASCR, University of Oxford and Fondazione IRCCS Istituto Nazionale dei Tumori) and several leading industrial partners (Evonik Nutrition & Care GmbH, iTeos Therapeutics, iOx Therapeutics, Oncoarendi Therapeutics, SMS-oncology and ttopstart BV).

The PRECIOUS project was awarded a 8,3 million Euro Horizon 2020 grant under the NMP-11 topic ‘nanomedicine therapy for cancer’. ttopstart is responsible for the project management and business aspects of PRECIOUS by ensuring a strong exploitation strategy and tight project management.